Are you Dr. Babu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
7910 W Jefferson Blvd
Ste 108
Fort Wayne, IN 46804Phone+1 260-484-8830Fax+1 260-483-1911
Summary
- Dr. Sunil Babu, MD is an oncologist in Fort Wayne, Indiana. He is currently licensed to practice medicine in Indiana, Ohio, and New York. He is affiliated with Lutheran Hospital of Indiana, Veterans Affairs Northern Indiana Health Care System, and Dupont Hospital.
Education & Training
Westchester Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008- Westchester Medical CenterResidency, Internal Medicine, 2000 - 2003
St. John's Medical CollegeClass of 1995
Certifications & Licensure
IN State Medical License 2008 - 2025
OH State Medical License 2021 - 2025
NY State Medical License 2003 - 2006- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2014
Clinical Trials
- A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Publications & Presentations
PubMed
- 106 citationsContinuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen A. Hussein
Journal of Clinical Oncology. 2020-09-10 - 77 citationsPhase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour
Cancer. 2017-03-15 - 56 citationsOutcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.Daniel A Pollyea, Keith W Pratz, Andrew H Wei, Vinod Pullarkat, Brian A Jonas
Clinical Cancer Research. 2022-12-15
Press Mentions
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid TumorsMarch 9th, 2021
Professional Memberships
- Member
